<SEC-DOCUMENT>0001710496-25-000002.txt : 20251017
<SEC-HEADER>0001710496-25-000002.hdr.sgml : 20251017
<ACCEPTANCE-DATETIME>20251017183752
ACCESSION NUMBER:		0001710496-25-000002
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20251015
FILED AS OF DATE:		20251017
DATE AS OF CHANGE:		20251017

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Emerson Erik C.
		CENTRAL INDEX KEY:			0001710496
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42545
		FILM NUMBER:		251401943

	MAIL ADDRESS:	
		STREET 1:		2300 WEST SAHARA AVENUE
		STREET 2:		SUITE 800 - #4012
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89102

	FORMER NAME:	
		FORMER CONFORMED NAME:	Emerson Erik
		DATE OF NAME CHANGE:	20170627

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apimeds Pharmaceuticals US, Inc.
		CENTRAL INDEX KEY:			0001894525
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				851099700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		100 MATAWAN RD
		STREET 2:		SUITE 325
		CITY:			MATAWAN
		STATE:			NJ
		ZIP:			07747
		BUSINESS PHONE:		848-201-5010

	MAIL ADDRESS:	
		STREET 1:		100 MATAWAN RD
		STREET 2:		SUITE 325
		CITY:			MATAWAN
		STATE:			NJ
		ZIP:			07747
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-10-15</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001894525</issuerCik>
        <issuerName>Apimeds Pharmaceuticals US, Inc.</issuerName>
        <issuerTradingSymbol>APUS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001710496</rptOwnerCik>
            <rptOwnerName>Emerson Erik C.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O APIMEDS PHARMACEUTICALS US, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>100 MATAWAN ROAD, SUITE 325</rptOwnerStreet2>
            <rptOwnerCity>MATAWAN</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07747</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Executive Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.92</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-10-15</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>215000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-10-15</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock, par value $0.01 per share</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>215000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>215000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the &quot;Plan&quot;) to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Nelson Mullins Riley &amp; Scarborough LLP, Attorney-in-Fact</signatureName>
        <signatureDate>2025-10-17</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
